Phaseline

Targets › ABCAM

ABCAM: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Nov 2026.

Open in Phaseline: the race on ABCAM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
KeyBioscienceKBP-336
Dual Amylin and Calcitonin Receptor agonist
CALCR, ABCAMPhase 2Osteoarthritis in the KneeNov 2026

Conditions

Osteoarthritis in the Knee (1)

Modalities

small molecule (1)

Companies

KeyBioscience (1)

Related targets

CALCR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.